Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Biotech M&A is picking back up according to BiopharmaDive

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 13, 2023 8:08pm

162 Views

Post# 35783489

RE:RE:Biotech M&A is picking back up according to BiopharmaDive

Barrons December 08, 2023 - Biotech Deals Are Heating Up. Why 2024 Could Be Even Hotter for M&A.

Biotech deals are heating up as the year comes to an end, and analysts say the hot streak will likely continue in coming months.

Biopharma M&A had stalled in recent years as the valuations of biotechs plunged. Biotech boards were unwilling to accept offers at prices that valued the companies far below where they had traded during the pandemic-era biotech boom, just a year or two earlier.

That has changed this year. According to an RBC count, the cumulative value of biopharma deals this year has been $128 billion, up from $61 billion in 2022.

The large-cap biopharma companies, meanwhile, have plenty of dry powder: According to RBC, they will have roughly $199 billion in cash by the end of the year. Dividends and stock buybacks, the RBC analysts wrote, are trending down, which could imply a focus on M&A.

“We believe Pharma will continue to be very aggressive on the M&A front,” Mizuho healthcare equity strategist Jared Holz wrote in an email to investors Wednesday.

Biotechs with obesity, immunology, and cancer assets have been in particular demand this year.

https://www.barrons.com/articles/biotech-abbvie-roche-stock-acquisitions-aa44cb59

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"